A recently published study by Future Market Insights predicts that the global autosomal dominant polycystic kidney disease treatment market will experience a value CAGR of 5.97% from 2023 to 2033, reaching an estimated value of US$ 2,140 million. The availability of special regulatory designations is one of the main.